DNA vaccines for cervical cancer: From bench to bedside

Chien-Fu Hung, Archana Monie, Ronald D. Alvarez, Tzyy Choou Wu

Research output: Contribution to journalArticle

Abstract

More than 99% of cervical cancers have been associated with human papillomaviruses (HPVs), particularly HPV type 16. The clear association between HPV infection and cervical cancer indicates that HPV serves as an ideal target for development of preventive and therapeutic vaccines. Although the recently licensed preventive HPV vaccine, Gardasil, has been shown to be safe and capable of generating significant protection against specific HPV types, it does not have therapeutic effect against established HPV infections and HPV-associated lesions. Two HPV oncogenic proteins, E6 and E7, are consistently co-expressed in HPV-expressing cervical cancers and are important in the induction and maintenance of cellular transformation. Therefore, immunotherapy targeting E6 and/or E7 proteins may provide an opportunity to prevent and treat HPV-associated cervical malignancies. It has been established that T cell-mediated immunity is one of the most crucial components to defend against HPV infections and HPV-associated lesions. Therefore, effective therapeutic HPV vaccines should generate strong E6/E7-specific T cell-mediated immune responses. DNA vaccines have emerged as an attractive approach for antigen-specific T cell-mediated immunotherapy to combat cancers. Intradermal administration of DNA vaccines via a gene gun represents an efficient way to deliver DNA vaccines into professional antigen-presenting cells in vivo. Professional antigen-presenting cells, such as dendritic cells, are the most effective cells for priming antigen-specific T cells. Using the gene gun delivery system, we tested several DNA vaccines that employ intracellular targeting strategies for enhancing MHC class I and class II presentation of encoded model antigen HPV-16 E7. Furthermore, we have developed a strategy to prolong the life of DCs to enhance DNA vaccine potency. More recently, we have developed a strategy to generate antigen-specific CD4+ T cell immune responses to further enhance DNA vaccine potency. The impressive preclinical data generated from our studies have led to several HPV DNA vaccine clinical trials.

Original languageEnglish (US)
Pages (from-to)679-689
Number of pages11
JournalExperimental and Molecular Medicine
Volume39
Issue number6
StatePublished - Dec 31 2007

Fingerprint

DNA Vaccines
Uterine Cervical Neoplasms
T-cells
Antigens
Papillomavirus Vaccines
Papillomavirus Infections
T-Lymphocytes
Vaccine Potency
Genes
Human papillomavirus 16
Firearms
Antigen-Presenting Cells
Immunotherapy
Papillomavirus E7 Proteins
Proteins
Gene Transfer Techniques
CD4 Antigens
Vaccines
Therapeutic Uses
Cellular Immunity

Keywords

  • Antigen presenting cells
  • Dendritic cells
  • Human papillomavirus type 16
  • Oncogene protein E7
  • Papillomavirus vaccines
  • Vaccination
  • Vaccines, DNA

ASJC Scopus subject areas

  • Biochemistry
  • Genetics

Cite this

DNA vaccines for cervical cancer : From bench to bedside. / Hung, Chien-Fu; Monie, Archana; Alvarez, Ronald D.; Wu, Tzyy Choou.

In: Experimental and Molecular Medicine, Vol. 39, No. 6, 31.12.2007, p. 679-689.

Research output: Contribution to journalArticle

Hung, Chien-Fu ; Monie, Archana ; Alvarez, Ronald D. ; Wu, Tzyy Choou. / DNA vaccines for cervical cancer : From bench to bedside. In: Experimental and Molecular Medicine. 2007 ; Vol. 39, No. 6. pp. 679-689.
@article{8b3ffb190357422599aaf9ab237790fd,
title = "DNA vaccines for cervical cancer: From bench to bedside",
abstract = "More than 99{\%} of cervical cancers have been associated with human papillomaviruses (HPVs), particularly HPV type 16. The clear association between HPV infection and cervical cancer indicates that HPV serves as an ideal target for development of preventive and therapeutic vaccines. Although the recently licensed preventive HPV vaccine, Gardasil, has been shown to be safe and capable of generating significant protection against specific HPV types, it does not have therapeutic effect against established HPV infections and HPV-associated lesions. Two HPV oncogenic proteins, E6 and E7, are consistently co-expressed in HPV-expressing cervical cancers and are important in the induction and maintenance of cellular transformation. Therefore, immunotherapy targeting E6 and/or E7 proteins may provide an opportunity to prevent and treat HPV-associated cervical malignancies. It has been established that T cell-mediated immunity is one of the most crucial components to defend against HPV infections and HPV-associated lesions. Therefore, effective therapeutic HPV vaccines should generate strong E6/E7-specific T cell-mediated immune responses. DNA vaccines have emerged as an attractive approach for antigen-specific T cell-mediated immunotherapy to combat cancers. Intradermal administration of DNA vaccines via a gene gun represents an efficient way to deliver DNA vaccines into professional antigen-presenting cells in vivo. Professional antigen-presenting cells, such as dendritic cells, are the most effective cells for priming antigen-specific T cells. Using the gene gun delivery system, we tested several DNA vaccines that employ intracellular targeting strategies for enhancing MHC class I and class II presentation of encoded model antigen HPV-16 E7. Furthermore, we have developed a strategy to prolong the life of DCs to enhance DNA vaccine potency. More recently, we have developed a strategy to generate antigen-specific CD4+ T cell immune responses to further enhance DNA vaccine potency. The impressive preclinical data generated from our studies have led to several HPV DNA vaccine clinical trials.",
keywords = "Antigen presenting cells, Dendritic cells, Human papillomavirus type 16, Oncogene protein E7, Papillomavirus vaccines, Vaccination, Vaccines, DNA",
author = "Chien-Fu Hung and Archana Monie and Alvarez, {Ronald D.} and Wu, {Tzyy Choou}",
year = "2007",
month = "12",
day = "31",
language = "English (US)",
volume = "39",
pages = "679--689",
journal = "Experimental and Molecular Medicine",
issn = "1226-3613",
publisher = "Korean Society of Med. Biochemistry and Mol. Biology",
number = "6",

}

TY - JOUR

T1 - DNA vaccines for cervical cancer

T2 - From bench to bedside

AU - Hung, Chien-Fu

AU - Monie, Archana

AU - Alvarez, Ronald D.

AU - Wu, Tzyy Choou

PY - 2007/12/31

Y1 - 2007/12/31

N2 - More than 99% of cervical cancers have been associated with human papillomaviruses (HPVs), particularly HPV type 16. The clear association between HPV infection and cervical cancer indicates that HPV serves as an ideal target for development of preventive and therapeutic vaccines. Although the recently licensed preventive HPV vaccine, Gardasil, has been shown to be safe and capable of generating significant protection against specific HPV types, it does not have therapeutic effect against established HPV infections and HPV-associated lesions. Two HPV oncogenic proteins, E6 and E7, are consistently co-expressed in HPV-expressing cervical cancers and are important in the induction and maintenance of cellular transformation. Therefore, immunotherapy targeting E6 and/or E7 proteins may provide an opportunity to prevent and treat HPV-associated cervical malignancies. It has been established that T cell-mediated immunity is one of the most crucial components to defend against HPV infections and HPV-associated lesions. Therefore, effective therapeutic HPV vaccines should generate strong E6/E7-specific T cell-mediated immune responses. DNA vaccines have emerged as an attractive approach for antigen-specific T cell-mediated immunotherapy to combat cancers. Intradermal administration of DNA vaccines via a gene gun represents an efficient way to deliver DNA vaccines into professional antigen-presenting cells in vivo. Professional antigen-presenting cells, such as dendritic cells, are the most effective cells for priming antigen-specific T cells. Using the gene gun delivery system, we tested several DNA vaccines that employ intracellular targeting strategies for enhancing MHC class I and class II presentation of encoded model antigen HPV-16 E7. Furthermore, we have developed a strategy to prolong the life of DCs to enhance DNA vaccine potency. More recently, we have developed a strategy to generate antigen-specific CD4+ T cell immune responses to further enhance DNA vaccine potency. The impressive preclinical data generated from our studies have led to several HPV DNA vaccine clinical trials.

AB - More than 99% of cervical cancers have been associated with human papillomaviruses (HPVs), particularly HPV type 16. The clear association between HPV infection and cervical cancer indicates that HPV serves as an ideal target for development of preventive and therapeutic vaccines. Although the recently licensed preventive HPV vaccine, Gardasil, has been shown to be safe and capable of generating significant protection against specific HPV types, it does not have therapeutic effect against established HPV infections and HPV-associated lesions. Two HPV oncogenic proteins, E6 and E7, are consistently co-expressed in HPV-expressing cervical cancers and are important in the induction and maintenance of cellular transformation. Therefore, immunotherapy targeting E6 and/or E7 proteins may provide an opportunity to prevent and treat HPV-associated cervical malignancies. It has been established that T cell-mediated immunity is one of the most crucial components to defend against HPV infections and HPV-associated lesions. Therefore, effective therapeutic HPV vaccines should generate strong E6/E7-specific T cell-mediated immune responses. DNA vaccines have emerged as an attractive approach for antigen-specific T cell-mediated immunotherapy to combat cancers. Intradermal administration of DNA vaccines via a gene gun represents an efficient way to deliver DNA vaccines into professional antigen-presenting cells in vivo. Professional antigen-presenting cells, such as dendritic cells, are the most effective cells for priming antigen-specific T cells. Using the gene gun delivery system, we tested several DNA vaccines that employ intracellular targeting strategies for enhancing MHC class I and class II presentation of encoded model antigen HPV-16 E7. Furthermore, we have developed a strategy to prolong the life of DCs to enhance DNA vaccine potency. More recently, we have developed a strategy to generate antigen-specific CD4+ T cell immune responses to further enhance DNA vaccine potency. The impressive preclinical data generated from our studies have led to several HPV DNA vaccine clinical trials.

KW - Antigen presenting cells

KW - Dendritic cells

KW - Human papillomavirus type 16

KW - Oncogene protein E7

KW - Papillomavirus vaccines

KW - Vaccination

KW - Vaccines, DNA

UR - http://www.scopus.com/inward/record.url?scp=38049174711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049174711&partnerID=8YFLogxK

M3 - Article

C2 - 18160838

AN - SCOPUS:38049174711

VL - 39

SP - 679

EP - 689

JO - Experimental and Molecular Medicine

JF - Experimental and Molecular Medicine

SN - 1226-3613

IS - 6

ER -